Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00879190 · ClinicalTrials.gov registry record · Phase 2
Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00879190: Completed Phase 2 study, sponsored by Stanford University.
NCT00879190 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 92 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00879190, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
Chorioamnionitis is an infection of the placenta and amniotic membranes (bag of waters) surrounding the baby inside of a pregnant woman prior to delivery. This infection is somewhat common and is routinely treated with antibiotics given to the mother both before and after the baby is born. Currently it is not known what is the best choice of antibiotics to treat this type of infection, but commonly used treatments include Unasyn (ampicillin/sulbactam) or ampicillin/gentamicin. We plan to compare these two different antibiotic regimens to see if one is better than the other at treating and preventing bad outcomes from chorioamnionitis in women and babies.
Interventions
- DRUG Unasyn
- DRUG Ampicillin/gentamicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00879190
The ClinicalTrials.gov registry entry for NCT00879190 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Unasyn is the first listed.
NCT00879190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00879190 about?
NCT00879190 is a clinical study titled "Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis". Chorioamnionitis is an infection of the placenta and amniotic membranes (bag of waters) surrounding the baby inside of a pregnant woman prior to delivery. This infection is somewhat common and is routinely treated with antibiotics given to the mother both before and after the baby is born. Currently...
What is the current status of trial NCT00879190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2009-05. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00879190?
The interventions under investigation include: Unasyn (DRUG), Ampicillin/gentamicin (DRUG).
Who is sponsoring clinical trial NCT00879190?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.